What You Need to Know:
- GSK has developed a vaccine against the respiratory syncytial virus (RSV) and is preparing to launch it in the United States in the fall.
- CEO Emma Walmsley does not anticipate as quick an uptake for the RSV vaccine as was seen with the company’s successful shingles vaccine, Shingrix.
- GSK considers the RSV vaccine a crucial component in their strategy to offset anticipated losses from expiring patent protections for some key HIV drugs.
- Walmsley indicated that distribution centers throughout the U.S. have already received shipments of the RSV vaccine.
- On Wednesday, GSK raised its financial forecast 2023 following stronger-than-predicted Q2 earnings.
- Shingrix, GSK’s shingles vaccine, is the firm’s best-selling product, generating 880 million pounds ($1.14 billion) just in Q2.
- RSV is a significant health risk, leading to a high incidence of pneumonia in toddlers and elderly citizens, resulting in numerous hospitalizations and fatalities annually.
- In June, GSK stated that it expects to price the RSV vaccine between $200 and $295 per dose but has not provided further details.
To read more, click here.
[Source: Reuters, July 26th, 2023]